Home / Novel Coronavirus
Novel Coronavirus SARS-CoV-2
An ongoing outbreak of a novel coronavirus (SARS-CoV-2) has raised
global concerns. It is identified as the cause of pneumonia with unknown
etiology. Since the early outbreak in Wuhan, China, it has subsequently
spread to all provinces of China and many other countries. The urgent
epidemic situation has spurred the development of antiviral drugs and
vaccines. As a leading service provider in the field of biological research
and drug discovery, Creative Biolabs provides fast & elaborate therapeutic
antibody discovery, drug candidates screening and vaccine development
services to help combat this outbreak.
Classification of SARS-CoV-2
Using unbiased sequencing and isolation from patients’ samples, SARS-
CoV-2 was identified as another clade within the Betacoronavirus genus,
Coronaviridae family. The two other strains of Betacoronaviruses-severe
acute respiratory syndrome coronavirus (SARS-CoV) and Middle East
respiratory syndrome coronavirus (MERS-CoV)—have caused more than
10,000 cumulative cases in the past two decades, with mortality rates of
10% for SARS-CoV and 37% for MERS-CoV. Similar to SARS-CoV and
MERS-CoV infections, patients with SARS-CoV-2 also exhibited symptoms
of viral pneumonia including fever, dyspnea, bilateral lung infiltration,
respiratory failure, even death.
Fig.1 Illustration and classification of 2019-nCoV.
Genome Characterization of SARS-CoV-2
With the help of high throughput sequencing and metagenomic analysis,
scientists have obtained full-length genome sequences from five patients
at the early stage of the outbreak. To date, a series of SARS-CoV-2
sequences have been uploaded and are available in GenBank and the
Sequence Read Archive (SRA).
Downloaded website: https://www.ncbi.nlm.nih.gov/genbank/SARS-CoV-2-
All of the sequences are almost identical to each other and share 79.5%
sequence identity to SARS-CoV. Furthermore, SARS-CoV-2 shows 96%
identity at the whole genome level to a bat coronavirus. The pairw